(PRWEB) May 21, 2014
Gout - Opportunity Analysis and Forecast to 2018 is a new opportunity analyzer market report announced by Reportstack. The new report estimates the 2013 sales for gout at approximately $989m across the 6MM. The acute gout segment of the market will double in size, reaching $337m in 2018 at a CAGR of 15%. The chronic gout market, which encompasses urate-lowering and prophylactic anti-inflammatory therapies, will experience even faster growth at a CAGR of 18.8%, and it will more than double in size, reaching over 1.9 billion in 2018.
With the current standard of care for gout already encompassing very successful and cheap treatments, the bar for success in the gout market is quite high. As a result, companies are shifting the focus of their research toward more severe gout cases, trying to address the greatest unmet needs. One of the major drivers of the gout market is the growing number of patients suffering from difficult-to-treat gout, for whom the standard therapies are inappropriate due to the presence of comorbidities, unresponsiveness, or intolerance. Targeting this patient niche is the strongest trend in the R&D strategies of the gout players. One of the greatest unmet needs, however, is improved physician and patient education regarding the seriousness of the disease and the importance of adhering to appropriate therapy.
Some KOLs indicated that earlier and more aggressive urate-lowering therapy is needed:
"I think we need more urate-lowering options, and I think we need IL-1 [interleukin-1]-targeted biologics or other anti-inflammatories that really suppress the gout flares [that are induced when aggressive urate-lowering is used], and then we could treat the acute gout better, as people would stick better to the urate-lowering therapy." - Key Opinion Leader.
To order this report: please visit http://www.reportstack.com/product/155986/opportunityanalyzer-gout-opportunity-analysis-and-forecast-to-2018.html.
The key findings from this report are:
Takeda, Menarini, Ipsen, Teijin Pharma, AstraZeneca, Novartis, Swedish Orphan, Biovitrum AB, Crealta Pharmaceuticals, BioCryst Pharmaceuticals, CymaBay Pharmaceutics and Pfizer are the companies mentioned in this report. More details about this report can be found by visiting Gout - Opportunity Analysis and Forecast to 2018 report.
Similar Reports on Gout:
Gouty Arthritis (Gout) - Pipeline Review, H1 2014 report which provides comprehensive information on the therapeutic development for Gouty Arthritis (Gout), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.
Gout - Epidemiology Forecast to 2023 report which forecast an increase in both the diagnosed incident cases and diagnosed prevalent cases of gout in the 6MM, from 1,374,065 diagnosed incident cases in 2013 to 1,649,065 diagnosed incident cases in 2023, at an annual growth rate (AGR) of 2.00%, and 13,750,047 diagnosed prevalent cases in 2013 to 17,625,944 diagnosed prevalent cases in 2023, at an AGR of 2.82%.
Reportstack is one of the leading distributors of market research reports in the world today. Reportstack provides access to over 50,000 company profiles and their strategic information like SWOT analysis, deals and partnerships analysis, merger & acquisition activity and new product launches. Reportstack is also a leader in the field of Healthcare and Pharma Market Research Reports.
Reportstack Market Research
Follow us: https://twitter.com/reportstack